Rezikuimod
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| Klinički podaci | |||
|---|---|---|---|
| Identifikatori | |||
| CAS broj | 144875-48-9 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 159603 | ||
| Hemijski podaci | |||
| Formula | C17H22N4O2 | ||
| Mol. masa | 314.382 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Trudnoća | B1(AU) C(US) | ||
| Pravni status | POM (UK) ℞-only (SAD) | ||
Rezikuimod (R-848) je lek koji deluje kao modifikator imunskog odgovora, i ima antivirusno i antitumorsko dejstvo. On se koristi kao topička krema u lečenju povreda kože[3] kao što su one uzrokovane Herpes simpleks virusom.[4][5] On se koristi kao pomoćno sredstvo za povećanje efikasnosti vakcina.[6] Rezikuimod ima nekoliko mehanizama dejstva. On je agonist TLR 7 i 8 receptora,[7] i ushodni regulator receptora opioidnog faktora rasta.[8]
Reference[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC (July 2008). „A phase II dose-ranging study of topical resiquimod to treat actinic keratosis”. The British Journal of Dermatology 159 (1): 205–10. DOI:10.1111/j.1365-2133.2008.08615.x. PMID 18476957.
- ↑ Wu JJ, Huang DB, Tyring SK (November 2004). „Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses”. Antiviral Research 64 (2): 79–83. DOI:10.1016/j.antiviral.2004.07.002. PMID 15498602.
- ↑ Fife KH, Meng TC, Ferris DG, Liu P (February 2008). „Effect of resiquimod 0,01 % gel on lesion healing and viral shedding when applied to genital herpes lesions”. Antimicrobial Agents and Chemotherapy 52 (2): 477–82. DOI:10.1128/AAC.01173-07. PMC 2224757. PMID 18039918.
- ↑ Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP (October 2007). „Resiquimod and other immune response modifiers as vaccine adjuvants”. Expert Review of Vaccines 6 (5): 835–47. DOI:10.1586/14760584.6.5.835. PMID 17931162.
- ↑ Hurst J, Prinz N, Lorenz M, Bauer S, Chapman J, Lackner KJ, von Landenberg P (February 2009). „TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells”. Immunobiology 214 (8): 683–91. DOI:10.1016/j.imbio.2008.12.003. PMID 19249118.
- ↑ Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ (August 2008). „Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function”. Experimental Biology and Medicine (Maywood, N.J.) 233 (8): 968–79. DOI:10.3181/0802-RM-58. PMID 18480416.
